Pacira BioSciences, Inc.
PCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $700,966 | $674,978 | $666,823 | $541,533 |
| % Growth | 3.9% | 1.2% | 23.1% | – |
| Cost of Goods Sold | $170,428 | $184,669 | $199,295 | $140,255 |
| Gross Profit | $530,538 | $490,309 | $467,528 | $401,278 |
| % Margin | 75.7% | 72.6% | 70.1% | 74.1% |
| R&D Expenses | $81,577 | $76,257 | $84,797 | $55,545 |
| G&A Expenses | $122,084 | $116,401 | $109,520 | $88,323 |
| SG&A Expenses | $294,099 | $269,441 | $254,516 | $199,345 |
| Sales & Mktg Exp. | $172,015 | $153,040 | $144,996 | $111,022 |
| Other Operating Expenses | $228,233 | $56,936 | $68,191 | $56,464 |
| Operating Expenses | $603,909 | $402,634 | $407,504 | $311,354 |
| Operating Income | -$73,371 | $87,675 | $60,024 | $89,924 |
| % Margin | -10.5% | 13% | 9% | 16.6% |
| Other Income/Exp. Net | $10,265 | -$25,974 | -$46,722 | -$33,520 |
| Pre-Tax Income | -$63,106 | $61,701 | $13,302 | $56,404 |
| Tax Expense | $36,454 | $19,746 | -$2,607 | $14,424 |
| Net Income | -$99,560 | $41,955 | $15,909 | $41,980 |
| % Margin | -14.2% | 6.2% | 2.4% | 7.8% |
| EPS | -2.15 | 0.91 | 0.35 | 0.95 |
| % Growth | -336.3% | 160% | -63.2% | – |
| EPS Diluted | -2.15 | 0.89 | 0.34 | 0.92 |
| Weighted Avg Shares Out | 46,245 | 46,222 | 45,521 | 44,262 |
| Weighted Avg Shares Out Dil | 46,245 | 51,979 | 46,538 | 45,630 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19,689 | $11,444 | $4,542 | $896 |
| Interest Expense | $16,569 | $17,310 | $35,576 | $28,996 |
| Depreciation & Amortization | $78,785 | $75,574 | $91,501 | $28,548 |
| EBITDA | $29,118 | $154,585 | $140,379 | $113,948 |
| % Margin | 4.2% | 22.9% | 21.1% | 21% |